NCT04352114View on ClinicalTrials.gov

A Study of LY3461767 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

January 13, 2021

Study Completion Date

January 13, 2021

Conditions
Healthy
Interventions
DRUG

LY3461767 - SC

Administered SC.

DRUG

LY3461767 - IV

Administered IV.

DRUG

Placebo - SC

Administered SC.

Trial Locations (3)

32117

Covance Clinical Research Inc, Daytona Beach

75247

Covance Dallas, Dallas

138623

Lilly Nus Centre for Clin Pharmacology, Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04352114 - A Study of LY3461767 in Healthy Participants | Biotech Hunter | Biotech Hunter